Bringing the power of biologics manufacturing innovation to the U.S.
As a global pioneer in biologics innovation, Enzene brings fully-connected continuous manufacturing to the U.S., providing unprecedented productivity, flexibility, and affordability to the global biotech community. With our state-of-the-art manufacturing site in Hopewell, New Jersey, biologics can now be developed and manufactured at a fraction of the cost and with a significantly reduced environmental footprint, all while maintaining quality and seamless scalability. The USDA/FDA-designed facility and our industry-leading technology both offer a unique opportunity for biologics manufacture in the western hemisphere.
Our first manufacturing site in New Jersey is at the heart of the US Northeast Corridor, providing easy access for many of our customers, and positioning us in a prime location for forming partnerships with new companies.
Our patented Fully Connected Continuous Manufacturing™ technology.
September 3, 2025
311 Pennington Rocky Hill Ro
Enzene is an end-to-end CIDMO with services spanning discovery, development, and commercial supply, operating integrated sites in Pune (India) and New Jersey (USA). As a pioneer in next-generation biologics technologies, Enzene is disrupting the existing biologics manufacturing paradigm with its patented EnzeneX™ technology, which was the first fully-connected continuous manufacturing™ (FCCM™) platform validated for commercial biologics supply.
We partner with innovators and biosimilar developers to deliver accelerated time-to-market, increased production yields, and cost reductions across a broad range of biologic modalities. Committed to pushing the boundaries of biologics manufacturing innovation, monoclonal antibody production can now be achieved at costs below $40 per gram. Our microbial and mammalian drug substance plants, as well as our sterile fill & finish plant in India are EU-GMP certified.